Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | GID4 | Q8IVV7 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 6/20 | 0.36 |
| ▸ | HTR2C | P28335 | 6/20 | 0.36 |
| ▸ | HTR2B | P41595 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044542 | 1.00 | PNMT (0.46) | PNMTGID4L3MBTL1GRIN2BKEAP1 | |
| SCHEMBL2835154 | 1.00 | PNMT (0.46) | PNMTGID4L3MBTL1GRIN2BKEAP1 | |
| SCHEMBL2835224 | 0.81 | MAPK1 (0.51) | PNMTGID4GRIN2BKEAP1MAPK1 | |
| Hydrochloric Acid SCHEMBL11012392 | 0.79 | MAPK1 (0.50) | PNMTGID4GRIN2BKEAP1MAPK1 | |
| SCHEMBL5086491 | 0.78 | HTR2C (0.51) | PNMTGID4HTR2AHTR2CHTR2B | |
| SCHEMBL1747061 | 0.74 | — | — | |
| SCHEMBL18071812 | 0.72 | HTR2C (0.62) | PNMTHTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL16363089 | 0.71 | ADRA2A (0.45) | GID4GRIN2BKEAP1DRD3TAAR1 | |
| SCHEMBL16363079 | 0.71 | ADRA2A (0.45) | GID4GRIN2BKEAP1DRD3TAAR1 | |
| SCHEMBL1745435 | 0.71 | ADRA2A (0.45) | GID4GRIN2BKEAP1DRD3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778243-A2 | SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | Athersys, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006004931-A2 | SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS, INC. | 2006-01-05 | — | — | US | claimed |
| US-7718647-B2 | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| EP-1778243-A2 | SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | Athersys, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006004931-A2 | SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | ATHERSYS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003990-A1 | Substituted azepine derivatives as serotonin receptor modulators | HTR5A, HTR4, HTR7 | PNMT 89/4885GID4 314/4885L3MBTL1 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.